Seagen (SGEN) – Analyst Ratings
-
RBC Says Seagen (SGEN) EV-302 and Amgen's (AMGN) Tarlatamab Looking Solid
-
Seagen (SGEN) gains after 'unsuprising' trial result
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SGEN Stock Lookup